Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Dr Menon believes that lifestyle modifications are “essential in managing diabetes and preventing complications.” His ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Clearside Biomedical Inc (CLSD) advances its wet AMD program with positive trial outcomes, while navigating financial and ...

The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

Dossiers are also under review in multiple countries globally. About AVT06/AVT29 AVT06/AVT29 is a recombinant fusion protein ...